Straits Times Index
3,439.88 +24.37 (+0.71%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.90 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
58,141.08 -2,000.27 (-3.33%) CMC Crypto 200
1,212.23 -48.95 (-3.88%)
INDV Feb 2025 15.000 call
| Previous close | 4.1000 |
| Open | N/A |
| Bid | 1.7000 |
| Ask | 5.5000 |
| Strike | 15.00 |
| Expiry date | 2025-02-21 |
| Day's range | 4.1000 - 4.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Pulling back 10% this week, Indivior's LON:INDV) five-year decline in earnings may be coming into investors focus
The last three months have been tough on Indivior PLC ( LON:INDV ) shareholders, who have seen the share price decline...
PR NewswireIndivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
- PR Newswire
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
